S90652 in Paediatric Hypertension

Safety and Effects on Blood Pressure of Daily Dose 0.025 to 0.135 Milligram Per Kilogram of S90625 a Paediatric Formulation of Perindopril, in Hypertensive Children - 24 Months

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00202592

Enrollment

Registered

2005-09-20

Start date

2003-11-30

Completion date

2010-04-30

Last updated

2018-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The aim of the study is to assess the long-term safety and effects on blood pressure of a paediatric formulation of perindopril in hypertensive children

Interventions

DRUGPerindopril

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Months to 17 Years

Healthy volunteers

Inclusion criteria

* Hypertensive children, who have been treated for four months at least with S90652, with safety and efficacy

Exclusion criteria

* Poorly controlled hypertension * Girls with signs of pubescence

Design outcomes

Primary

Measure	Time frame
Clinical safety assessed from the patient's (parents) complaints and clinical follow-up	—

Secondary

Measure	Time frame
Blood pressure	—

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026